נגישות
menu      
Advanced Search
Syntax
Search...
Volcani treasures
About
Terms of use
Manage
Community:
אסיף מאגר המחקר החקלאי
Powered by ClearMash Solutions Ltd -
Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone
Year:
1984
Source of publication :
Circulatory Shock
Authors :
Ezra, David
;
.
Volume :
13
Co-Authors:
Feuerstein, G., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Lux Jr., W.E., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Snyder, F., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Ezra, D.
Faden, A.I.
Facilitators :
From page:
255
To page:
260
(
Total pages:
6
)
Abstract:
Platelet-activating factor (PAF), a vasoactive phospholipid implicated in anaphylactic reactions, causes severe hypotension in experimental animals that is highly resistant to pharmacological therapy. In the present studies, we showed that PAF (1 nmol/600 g body weight, IV) produced profound hypotension in unanesthetized guinea pigs that was promptly and completely reversed by thyrotropin-releasing hormone (TRH) (2 mg/kg, IV) or by the synthetic TRH analog MK771 (2 mg/kg, IV). TRH also reversed this hypotension when administered intracerebroventricularly (ICV) at a dose (0.02 mg/kg) that was systemically ineffective. The opiate receptor antagonist naloxone (5 mg/kg) was less effective than TRH in reversing the cardiovascular consequences of PAF administration. These data suggest that TRH reverses PAF-induced shock through central receptor-mediated mechanisms. This therapeutic action of TRH may partially account for the beneficial cardiovascular effects of this peptide in anaphylactic shock.
Note:
Related Files :
animal experiment
animal model
Animals
Male
protirelin
therapy
Thiazolidines
Show More
Related Content
More details
DOI :
Article number:
Affiliations:
Database:
Scopus
Publication Type:
article
;
.
Language:
English
Editors' remarks:
ID:
27178
Last updated date:
02/03/2022 17:27
Creation date:
17/04/2018 00:28
Scientific Publication
Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone
13
Feuerstein, G., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Lux Jr., W.E., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Snyder, F., Neurobiology Research Unit, Uniformed Services, University of the Health Sciences, Bethesda, MD 20814, United States
Ezra, D.
Faden, A.I.
Hypotension produced by platelet-activating factor is reversed by thyrotropin-releasing hormone
Platelet-activating factor (PAF), a vasoactive phospholipid implicated in anaphylactic reactions, causes severe hypotension in experimental animals that is highly resistant to pharmacological therapy. In the present studies, we showed that PAF (1 nmol/600 g body weight, IV) produced profound hypotension in unanesthetized guinea pigs that was promptly and completely reversed by thyrotropin-releasing hormone (TRH) (2 mg/kg, IV) or by the synthetic TRH analog MK771 (2 mg/kg, IV). TRH also reversed this hypotension when administered intracerebroventricularly (ICV) at a dose (0.02 mg/kg) that was systemically ineffective. The opiate receptor antagonist naloxone (5 mg/kg) was less effective than TRH in reversing the cardiovascular consequences of PAF administration. These data suggest that TRH reverses PAF-induced shock through central receptor-mediated mechanisms. This therapeutic action of TRH may partially account for the beneficial cardiovascular effects of this peptide in anaphylactic shock.
Scientific Publication
You may also be interested in